GO
Loading...

Novartis AG

More

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • *Allegations follow corruption accusations in China, Iraq. LONDON/ WARSAW, April 14- GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq.

  • April 10- Rite Aid Corp, the third-largest U.S. drugstore operator, forecast fiscal 2015 sales above analysts' estimates as it benefits from the launch of new generic drugs and enrolls more customers in its loyalty programs.

  • PARIS/ ZURICH, April 10- France's competition authority is investigating drugmakers Roche and Novartis on suspicion they were involved in anti-competitive practices in relation to eye disease treatments, the companies said on Thursday.

  • MUMBAI, April 9- India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

  • Chief Justice John Roberts on Tuesday asked generic drug manufacturers to respond to a request from Teva Pharmaceutical Industries Ltd seeking to prevent a lower court ruling from taking effect while the high court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug, Copaxone.

  • WASHINGTON, April 7- Teva Pharmaceutical Industries Ltd asked the U.S. Supreme Court on Monday to stop a lower court ruling from going into effect while the justices consider an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.

  • WASHINGTON, April 7- Teva Pharmaceutical Industries Inc on Monday asked the U.S. Supreme Court to prevent an appeals court ruling from going into effect while the justices consider the company's appeal in a patent fight over top-selling multiple sclerosis drug Copaxone.

  • April 6- Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. The U.S. Food and Drug Administration has granted "breakthrough" status for palbociclib.

  • ZURICH, April 3- Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. In a hearing that took place on March 28, the Delhi court ordered that Biocon cannot manufacture, sell or export vildagliptin until the next court hearing, Novartis said in an emailed statement.

  • April 2- Bill Gates, the World Bank and other donors are stepping up efforts to fight neglected tropical diseases in Africa and other low-income regions with a $240 million injection of new funding. The new collaboration includes $50 million from the Bill& Melinda Gates Foundation and $50 million from the Children's Investment Fund Foundation.

  • March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis acquired the license to develop and market the treatment from Genentech, a unit of the Roche Holding AG, for an upfront payment of $9.5 million in November 2012.

  • WASHINGTON, March 31- The U.S. Supreme Court on Monday agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over top-selling multiple sclerosis drug Copaxone, a move that could deter generic manufacturers from introducing cheaper versions onto the market as soon as May.

  • U.S. justices agree to hear Teva's Copaxone appeal Monday, 31 Mar 2014 | 9:36 AM ET

    By agreeing to hear the case, the high court cast into doubt a July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd. The appeals court upheld some of nine patents involved in the drug, or portions thereof, but declared several invalid, meaning patent protections were set to expire in May 2014 instead of September 2015.

  • European shares extend gains, Novartis rallies Monday, 31 Mar 2014 | 7:45 AM ET

    *Novartis rises on positive results for heart drug. LONDON, March 31- European equities hit a three-week high on Monday, with Novartis stronger due to good results for its heart drug and miners performing well on expectations that China might stimulate its economy.

  • *Novartis to seek approval with global regulators. ZURICH, March 31- Novartis has ended a late-stage clinical trial of a chronic heart failure drug early, following strong interim results, giving the Swiss drugmaker a boost after recent setbacks to another heart failure medicine.

  • ZURICH, March 31- Swiss drugmaker Novartis is set to end a late-stage clinical trial of a chronic heart failure drug early, following strong interim results. Novartis said it would start talks with global health regulators about filing for drug for approval.

  • March 26- Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection, sending shares down 34 percent in premarket trade. Insmed compared the drug, in combination with a standard treatment, with a combination of placebo and the standard treatment.

  • *Sanofi hopes to deliver first doses in late 2015. *Sanofi has spent over 1.3 bln euros on project.

  • WASHINGTON, March 24- The U.S. Supreme Court on Monday for the second time did not announce whether it would hear an appeal by Teva Pharmaceutical Industries Ltd in a patent fight with generic competitors over a top-selling multiple sclerosis drug.

Most Popular Video

Wednesday, 16 Apr 2014 | 4:40 AM ET

Loyalists around the world have embraced it as the cryptocurrency of the future, but some big names on the street differ widely in their beliefs about bitcoin. The Oracle of Omaha thinks it's a "joke." Tech entrepreneur Marc Andreessen counters that Buffett is out of touch, while bitcoin believers like Jonathan Rumion fully embrace the digital currency by buying groceries with bitcoin and even getting paid in bitcoin. CNBC's Mary Thompson reports.

Wednesday, 16 Apr 2014 | 3:00 AM ET

European shares opened higher on Wednesday as better-than-expected Chinese growth data buoyed sentiment.

Wednesday, 16 Apr 2014 | 2:00 AM ET

Brady Dougan, CEO of Credit Suisse, says the bank's fixed income business is "strong", while the investment banking arm has performed well.